Introduction
MUM, uveal melanoma
UVEAL MELANOMA
Edited by: Cunzhong Yuan, Shandong University, ChinaReviewed by: Di Yu, Uppsala University, Sweden; Erkko Ylösmäki, Rokote Laboratories Finland Oy, Finland†These authors have contributed equally to this work and share senior authorshipMetastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically experience durable responses to immune checkpoint inhibitors (ICIs). Oncolytic viruses (OV) represent a novel approach to immunotherapy for patients with MUM.